Scarica l'app Stockscreener
1.97
1.01%
-0.02
Dopo l'orario di chiusura:
1.97
Precedente Chiudi:
$1.99
Aprire:
$1.99
Volume 24 ore:
38,247
Relative Volume:
2.30
Capitalizzazione di mercato:
$181.60M
Reddito:
$47.04M
Utile/perdita netta:
$-63.98M
Rapporto P/E:
-2.443
EPS:
-0.8064
Flusso di cassa netto:
$-34.39M
1 W Prestazione:
-10.45%
1M Prestazione:
+2.07%
6M Prestazione:
-11.66%
1 anno Prestazione:
+4.18%
Intervallo 1D:
$1.95
$1.995
Intervallo di 1 settimana:
$1.95
$2.40
Portata 52W:
$1.29
$3.5107
Innate Pharma Adr Stock (IPHA) Company Profile
Nome
Innate Pharma Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta IPHA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IPHA
Innate Pharma Adr
|
1.97 | 183.41M | 47.04M | -63.98M | -34.39M | -0.8064 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Innate Pharma Adr Stock (IPHA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-09-18 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-07-28 | Iniziato | BTIG Research | Buy |
| 2021-09-03 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-12-15 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-11-24 | Iniziato | Goldman | Neutral |
Mostra tutto
Innate Pharma Adr Borsa (IPHA) Ultime notizie
Innate Pharma FY2025 EPS Forecast Increased by HC Wainwright - MarketBeat
Innate Pharma (NASDAQ:IPHA) Stock Price Down 3.9%Time to Sell? - MarketBeat
Lucid Capital Markets initiates coverage on Innate Pharma stock with Buy rating - Investing.com India
Goldman Sachs Sticks to Their Hold Rating for Innate Pharma SA (IPHYF) - Barchart.com
Leerink Partnrs Forecasts Innate Pharma Q3 Earnings - Defense World
Innate Pharma FY2025 EPS Estimate Increased by HC Wainwright - MarketBeat
Innate Pharma (NASDAQ:IPHA) Downgraded by HC Wainwright to “Neutral” - Defense World
Innate Pharma (NASDAQ:IPHA) Given “Market Perform” Rating at Leerink Partners - Defense World
Leerink Partners downgrades Innate Pharma stock on shift to ADC strategy - Investing.com
Innate Pharma SA Reports First Half 2025 Financial Results - TipRanks
Innate Pharma H1 2025 slides: strategic refocus on key assets extends cash runway By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma’s Q2 2025 focus on strategic assets - Investing.com
Innate Pharma H1 2025 slides: strategic refocus on key assets extends cash runway - Investing.com
Innate Pharma Reports First Half 2025 Business Update and Financial Results - Placera.se
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Short Interest Down 25.8% in August - MarketBeat
Innate Pharma (NASDAQ:IPHA) Trading 1.7% HigherWhat's Next? - MarketBeat
Innate Pharma (NASDAQ:IPHA) Trading 1.7% Higher – Here’s What Happened - Defense World
Arm Holdings PLC Releases Q2 2025 Financial Report Amid Market Challenges - The Globe and Mail
How strong is Innate Pharma S.A. Depositary Receipt company’s balance sheetSuperior risk-adjusted returns - Jammu Links News
Innate Pharma stock initiated with Buy rating at BTIG on cancer therapy potential - Investing.com
Non-Hodgkin’s Lymphoma Market Forecast to Surge with Growing Adoption of Targeted and Cell-Based Therapies | DelveInsight - GlobeNewswire Inc.
Innate Pharma (NASDAQ:IPHA) Trading 1.7% Higher – What’s Next? - Defense World
Exchange Traded Concepts LLC Has $112,000 Stock Position in Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) - Defense World
Why Kingsoft Cloud Holdings Stock Plummeted by Nearly 8% Today - The Globe and Mail
Should You Buy, Hold, or Sell PDD Holdings Stock Before Q1 Earnings? - The Globe and Mail
Earnings call transcript: Innate Pharma Q1 2025 earnings reveal strategic focus By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q1 2025 earnings reveal strategic focus - Investing.com India
Innate Pharma Q1 2025 slides: pipeline advances and Sanofi partnership strengthen outlook - Investing.com
Innate Pharma Q1 2025 slides: pipeline advances and Sanofi partnership strengthen outlook By Investing.com - Investing.com South Africa
Innate Pharma reports promising preclinical results for cancer drug IPH4502 By Investing.com - Investing.com India
Innate Pharma stock surges on promising preclinical data By Investing.com - Investing.com South Africa
Innate Pharma reports promising preclinical results for cancer drug IPH4502 - Investing.com
H.C. Wainwright maintains $11 target on Innate Pharma stock - Investing.com
Earnings call: Innate Pharma Q3 2024 results highlight oncology pipeline - Investing.com
AZN Stock Price and Chart — NASDAQ:AZN - TradingView
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study - Nasdaq
What is the current Price Target and Forecast for Innate Pharma (IPHA) - Zacks Investment Research
Innate, Sanofi ink licensing deal for NK cells - MarketWatch
Innate Pharma: AstraZeneca To Discontinue INTERLINK-1 Monalizumab Combination Trial - Nasdaq
Innate Pharma Gets $50 Million From AstraZeneca as Monalizumab Phase 3 Lung Cancer Trial Begins - Equities.com
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - FinancialContent
Innate Pharma (IPHA) Stock Price, News & Analysis - MarketBeat
Innate Pharma Share Price ADR EACH REPR 1 ORD SPON - Hargreaves Lansdown
AstraZeneca and Innate Pharma announce global co-development and commercialisation collaboration for IPH2201 in immuno-oncology - AstraZeneca
Innate Pharma Adr Azioni (IPHA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.62%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):